Published: November 2014
Roots Analysis has announced the addition of “Immune Checkpoint Inhibitors Market, 2014-2024” report to their offering. The study offers a comprehensive view of the emerging market of CTLA-4, PD-1, PD-L1 and several novel immune checkpoint inhibitors (IDO-1, IDO-2, KIR, OX40, CD70, LAG-3 and more).
Apurva Bhardwaj, the principal analyst, said, “Owing to the highly responsive nature of the market, marked by the presence of new entrants and established companies, the future looks highly promising. The study includes valuable insights encompassing the prevailing competitive market of oncology, the common platform created by partnering activities and the forecast for marketed / late stage development products.”
Bhardwaj further stated, “The market is currently characterized by the presence of three marketed drugs and 25 drugs in clinical development.
Amongst other things, the report covers:
With several blockbusters in the pipeline, Roots Analysis predicts the market to grow at a CAGR of 24.1% over the coming decade.
The 192 page report includes detailed profiles and an assessment of the clinical research pipeline of many companies mentioned below. In addition, there are several other companies which have molecules in discovery / preclinical stages.
For additional details, please visit http://www.rootsanalysis.com/reports/market-reports/view_document/immune-checkpoint-inhibitors-market-2014-2024/73.html
About Roots Analysis
Roots Analysis is a specialist market research company, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like us to help you with your growing business needs, get in touch at email@example.com
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry